News update for our clinical ADC candidate, TUB-040, at the upcoming 15th Biennial Ovarian Cancer Research Symposium organized by the Rivkin Center and the American Association for Cancer Research. On September 21, our VP Clinical &Translational Development, Yariv Houvras, will present a poster on the nonclinical safety evaluation and the design of our recently initiated clinical Phase I/IIa trial with TUB-040, our NaPi2b-targeting ADC candidate that also gained Fast Track designation by the FDA for the treatment of patients with platinum-resistant OvarianCancer last July.
